JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure
Open accessThe DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Abstract
Joint Working Groups: The Japanese Circulation Society; the Japanese Heart Failure Society; the Japanese Association for Thoracic Surgery; the Japanese Society of Hypertension; Japanese Society of Echocardiography; the Japanese Society for Cardiovascular Surgery; Japanese College of Cardiology; the Japanese Association of Cardiac Rehabilitation; the Japan Society of Ultrasonics in Medicine; the Japan Diabetes Society; Japanese Heart Rhythm Society; “the Study Group on Idiopathic Cardiomyopathy” supported by the Health and Labor Sciences Research Grant on Intractable Diseases; and “the Study Group on the Multi-center Observational Study of Dilated- phase Hypertrophic Cardiomyopathy”, supported by the “Practical Research Project for Rare/intractable Diseases by the Japan Agency for Medical Research and Development. In March 2018, the JCS/Japanese Heart Failure Society jointly published the 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure. In this revised edition, a research group comprised of members recommended by 11 academic societies, including the JCS, Japanese Heart Failure Society, Japanese Association for Thoracic Surgery, Japanese Society of Hypertension, Japanese Society of Echocardiography, Japanese Society for Cardiovascular Surgery, Japanese College of Cardiology, Japanese Association of Cardiac Rehabilitation, Japan Society of Ultrasonics in Medicine, Japan Diabetes Society, and Japanese Heart Rhythm Society, was organized. In addition, 2 study groups participated in this revision, the “Survey and research on idiopathic myopathy” of the Research Program on Rare and Intractable Diseases, Ministry of Health, Labour and Welfare, and “A Multicenter Registered Observational Study on the Dilated Phase of Hypertrophic Cardiomyopathy” of the Japan Agency for Medical Research and Development Practical Research Project for Rare/Intractable Diseases. Taking the latest guidelines of Western countries into considerations, we published the revised edition as the guidelines presenting standard treatment of acute and chronic heart failure by incorporating evidence and actual clinical experience in Japan. The major change in this revised edition is the integration of the previous heart failure treatment guidelines, which were separated into acute heart failure and chronic heart failure. This change was based on the recognition that separate treatment guidelines into acute and chronic sections is not realistic because many patients with acute heart failure are acute exacerbation of chronic heart failure and the seamless management from the acute to chronic phase is necessary. The main points of the 2017 revised edition are as follows:1)The definition of heart failure was clarified and a definition easy to understand for the general public was newly described.2)Heart failure, stage with progression of the risk, and treatment target were newly described.3)Heart failure was classified based on the left ventricular ejection fraction (LVEF).4)The heart failure diagnosis algorithm was newly presented.5)Management concerning prevention of heart failure was newly added.6)The heart failure treatment algorithm was newly presented.7)The descriptions of the clinical state and treatment of comorbidities were expanded.8)The flow chart of acute heart failure treatment based on the time course and clinical state was newly presented.9)The treatment algorithm of severe heart failure with a ventricular assist device (VAD) was newly presented.10)The description of palliative care was expanded. After the publication of the revised edition, therapeutic drugs described in “Future Treatment” were approved and important evidence for pharmacologic therapy and nonpharmacologic therapy has been reported. These changes are related directly to routine clinical practice for heart failure and the contents were important and should be reflected in the guidelines. Therefore, it was decided to publish the JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure without waiting for the next revision. The main revised points included in this Focused Update are as follows:1.General Principles: Proposal of a new LVEF-based classification and changes in the definition about heart failure with mid-range EF (HFmrEF) and heart failure with recovered EF (HFrecEF) (2017 edition, Chapter II; Focused Update, Chapter 1). Based on the importance of time-dependent changes in LVEF, new classification of heart failure as HFrecEF, heart failure with worsened EF (HFworEF), and heart failure with unchanged EF (HFuncEF) was presented.2.Basic Principles for the Treatment of Heart Failure: Updated treatment algorithms for heart failure (2017 edition, Chapter V; Focused Update, Chapter 2). Newer drugs including If channel blocker or HCN channel blocker, ivabradine, angiotensin receptor neprilysin inhibitor (ARNI), sacubitril and valsartan, and sodium glucose cotransporter 2 (SGLT2) inhibitor were incl
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citationThe Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214
The SOLVD Investigators* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250501 · Cited by 8,029
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery
Leon, M. B., Smith, C. R., Mack, M., Miller, D. C., Moses, J. W., Svensson, L. G., Tuzcu, E. M., Webb, J. G., Fontana, G. P., Makkar, R. R., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008232 · Cited by 7,205
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Metadata
- Authors
- Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., Sakata, Y., Shimizu, W., Yamamoto, K., Bando, Y., Iwasaki, Y.-K., Kinugasa, Y., Mizote, I., Nakagawa, H., Oishi, S., Okada, A., Tanaka, A., Akasaka, T., Ono, M., Kimura, T., Kohsaka, S., Kosuge, M., & Momomura, S.-I.
- Venue
- Journal of Cardiac Failure
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 27
- Issue
- 12
- Pages
- 1404-1444
- ISSN
- 1071-9164 (ISSN-L)
- OpenAlex
- W3201722621
- Cited by
- 158
- References
- 76
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. https://app.cochat.ai/papers/10.1016/j.cardfail.2021.04.023
- The paper
- Tsutsui, H., Ide, T., Ito, H., Kihara, Y., Kinugawa, K., Kinugawa, S., Makaya, M., Murohara, T., Node, K., Saito, Y., Sakata, Y., Shimizu, W., Yamamoto, K., Bando, Y., Iwasaki, Y.-K., Kinugasa, Y., Mizote, I., Nakagawa, H., Oishi, S., . . . Momomura, S.-I. (2021). JCS/JHFS 2021 Guideline Focused Update on Diagnosis and Treatment of Acute and Chronic Heart Failure. Journal of Cardiac Failure. https://doi.org/10.1016/j.cardfail.2021.04.023
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.